Vizsgálati helyszín
Oncolab S.R.L.
Craiova, 200385, RomániaEU-13 felzárkózó országMég nincs intézményhez kötve
- 16futó vizsgálat
- 11lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis22 vizsgálat
- 2. fázis3 vizsgálat
- 2/3. fázis2 vizsgálat
- Állapot
- Lezárult11 vizsgálat
- Fut, nem toboroz9 vizsgálat
- Toboroz6 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- AstraZeneca3 vizsgálat
- H e x a l AG2 vizsgálat
- Maia Biotechnology2 vizsgálat
- Mirati Therapeutics Inc.2 vizsgálat
- AbbVie1 vizsgálat
- és még 17
Futó vizsgálatok
Még nem toboroz
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
NCT07340658· 3. fázis· Rovi Pharmaceuticals Laboratories· Forrás
Toboroz
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
NCT06908304· 3. fázis· Maia Biotechnology· Forrás
Toboroz
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN)
2024-515538-34-00· 2/3. fázis· Inhibrx Biosciences Inc.· Forrás
Fut, nem toboroz
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
NCT06687369· 3. fázis· mAbxience Research S.L.· Forrás
Fut, nem toboroz
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab treatment after participation in previous studies (CGME751A12101 or CGME751A12301)
2024-513160-25-00· 3. fázis· H e x a l AG· Forrás
Toboroz
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277· 3. fázis· Bayer· Forrás
Fut, nem toboroz
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients
2023-507448-36-00· 3. fázis· Samsung Bioepis Co. Ltd.· Forrás
Fut, nem toboroz
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma
2023-503288-40-00· 3. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
THIO Sequenced With Cemiplimab in Advanced NSCLC
NCT05208944· 2. fázis· Maia Biotechnology· Forrás
Toboroz
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976· 2/3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318· 3. fázis· Aragon Pharmaceuticals, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Fut, nem toboroz
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265· 3. fázis· Immutep S.A.S.· Forrás
Toboroz
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
2023-507097-41-01· 3. fázis· Shanghai Junshi Biosciences Co. Ltd.· Forrás
Lezárult
A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer
2024-514048-98-00· 3. fázis· Celltrion Inc.· Forrás
Lezárult
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer
2023-506882-70-00· 3. fázis· H e x a l AG· Forrás
Fut, nem toboroz
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575· 2. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692· 3. fázis· AstraZeneca· Forrás
Lezárult
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
NCT05153239· 3. fázis· PharmaMar· Forrás
Fut, nem toboroz
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135· 3. fázis· Mirati Therapeutics Inc.· Forrás
Lezárult
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04623775· 2. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT02273375· 3. fázis· Canadian Cancer Trials Group· Forrás
Hibát jelzek